CTRI/2019/07/020324招募中2 期
Randomised placebo controlled double blind clinical trial on the efficacy of AYUSHMANAS in the management of Smriti dourbalya (Cognitive deficit)â?? - AYUSHMANAS in CD
CCRAS MINISTRY OF AYUSH0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Children of either sex aged in between 8 to 13 years.
- •2. Children with Intelligence Quotient 63 â?? 80 as per BKT
- •3. Willing and able to participate for 6 months
- •(Consent to be obtained from Parent(s) / Guardian(s)/ Assent from children wherever possible).
排除标准
- •1.Children with a history of peptic ulcer disease, any gastric or duodenal surgery, gastrointestinal (GI) bleeding or other GI disorders.
- •2.Children with severe infection and/or clinically significant hepatic, respiratory, renal, cardiac or hematological disorders.
- •3.Children with abnormal laboratory values at admission in to the study: serum creatinine 1.2 > mg/dl, SGOT, SGPT >3times upper limit of normal; serum Bilirubin or Alkaline phosphatase >1.5 times upper limit of normal
- •4.Patientâ??s guardian who cannot be relied upon to comply with the test procedures or are unwilling to give informed consent.
- •5.The Children had any intramuscular, intra-articular or intravenous carticosteroids within 4 weeks prior to study entry.
- •6.The Children with a history of recent and clinically significant drug abuse.
- •7.The Children with pre-existing blood dyscrasias, eg., bone marrow hypoplasia, leukopenia, thrombocytopenia etc.
- •8.The Children is unlikely to comply with protocol, eg., un cooperative attitude, inability to return for follow-up visits, and unlikelihood of complete study.
- •9.Children in whom another investigational drug was used with in 3 months prior to entry in this study.
- •10.Children with poorly controlled epilepsy
- •(H/o attack in last 3 months).
- •11.Children to whom BKT canâ??t be administered for any reason
研究者
相似试验
进行中(未招募)
1 期
The effect of EA-230 on the immuneresponseEUCTR2014-002481-78-NLExponential Biotherapies Inc60
已完成
不适用
Randomized double blind placebo-controlled clinical safety, tolerability and pharmacokinetic/-dynamic study on the effects of escalating single intravenous doses of EA-230 on the innate immune response during experimental human endotoxemiaNL-OMON40791Exponential Biotherapies inc.60
尚未招募
2 期
To Investigate the anti-proliferative and anti-cancer potential of Moclobemide (an anti-depression drug) in castration resistant prostate cancer.CTRI/2023/01/048893ICMR-Product Development Centre at AIIMS New Delhi
已完成
1 期
Study comparing two methods of intervention for pain control following total knee replacementCTRI/2018/08/015386Sunshine Hospitals150
招募中
不适用
Comparing the effect of dietary regimen with and without Lobub (a complex drug) for treatment of male subfertilityMale Infertility.Male InfertilityIRCT201508036541N8Vice chancellor for research of Shiraz University of Medical Sciences40
